ストックスクリーナーアプリを入手
55.91
2.27%
1.24
アフターアワーズ：
55.91
前日終値:
$54.67
開ける：
$55.54
24時間の取引高:
1.73M
Relative Volume:
1.26
時価総額：
$8.05B
収益：
-
当期純損益:
$-766.63M
株価収益率:
-9.80
EPS:
-5.7051
ネットキャッシュフロー:
$-712.55M
1週間 パフォーマンス:
+3.00%
1か月 パフォーマンス:
-11.31%
6か月 パフォーマンス:
+73.96%
1年 パフォーマンス:
-22.24%
1日の値動き範囲:
$55.25
$57.65
1週間の範囲:
$53.17
$57.65
52週間の値動き範囲:
$27.66
$72.66
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
55.91 | 7.87B | 0 | -766.63M | -712.55M | -5.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 繰り返されました | Needham | Buy |
| 2025-09-12 | 開始されました | Goldman | Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360
Vaxcyte completes enrollment in two Phase 3 trials for VAX-31 - Investing.com Australia
Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials - GuruFocus
Vaxcyte fills key adult vaccine trial, sets up 2026 Phase 3 data - Stock Titan
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative - simplywall.st
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet - simplywall.st
Responsive Playbooks and the PCVX Inflection - Stock Traders Daily
Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31 - Drug Topics
PCVX PE Ratio & Valuation, Is PCVX Overvalued - Intellectia AI
JPMorgan Chase & Co. Acquires 366,266 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc.: Fundamental Analysis and Financial Ratings | 1PCVX | US92243G1085 - marketscreener.com
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet - Investing.com Australia
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCV - GuruFocus
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Advances VAX-31 Vaccine with Positive Study Resul - GuruFocus
Vaxcyte (NASDAQ:PCVX) CAO Sells $105,138.44 in Stock - MarketBeat
Vaxcyte (PCVX) Price Target Decreased by 17.52% to 83.49 - MSN
Vaxcyte : March Investor Presentation (6862ba) - marketscreener.com
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate - The Manila Times
Vaxcyte Advances VAX-31 into Phase 3 Clinical Program Following Positive Phase 1/2 Study Results in Older Adults - Quiver Quantitative
Vaxcyte publishes positive Vax-31 phase 1/2 adult study results in The Lancet Infectious Diseases - marketscreener.com
A 31-strain pneumonia shot showed strong immune responses in adults 50+ - Stock Titan
Vaxcyte SVP, finance & CAO Cowan sells $105k in stock - Investing.com UK
Vaxcyte Publishes Positive Vax-31 Phase 1/2 Adult Study Results In The Lancet Infectious Diseases - TradingView
Positive VAX-31 Phase 1/2 Adult Data Published in The - GlobeNewswire
Vaxcyte (PCVX) finance SVP sells 1,892 shares under 10b5-1 plan - Stock Titan
Vaxcyte Completes $632.5 Million Public Offering of Common Stock - Global Legal Chronicle
Elvia Cowan sells shares; RSU vesting at PCVX (NASDAQ: PCVX) - Stock Titan
Forecast Cut: Is Vaxcyte Inc affected by consumer sentimentPortfolio Return Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Vaxcyte, Inc. $PCVX Shares Sold by Aquatic Capital Management LLC - MarketBeat
HighVista Strategies LLC Acquires 53,345 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
PCVX Technical Analysis & Stock Price Forecast - Intellectia AI
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Quantisnow
Love a little risk? Wall Street sees massive upside in Vaxcyte stock - MSN
Pivotal bioVenture Partners Boosts Stake in Vaxcyte - National Today
Pivotal bioVenture Partners Investment Advisor LLC Raises Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc Stock (ISIN: US92242T1016) Slides on Major Investor Stake Cut - AD HOC NEWS
Vaxcyte Shares Decline as Capital Research Global Investors Reduces Stake - National Today
Vaxcyte, Inc. $PCVX Holdings Lowered by Capital Research Global Investors - MarketBeat
Latest PCVX NewsVaxcyte to Report Fourth Quarter and Full Y... - Stock Titan
Victory Capital Management Inc. Lowers Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Aug PostEarnings: Can Vaxcyte Inc continue delivering strong returnsQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Vaxcyte (NASDAQ:PCVX) CAO Elvia Cowan Sells 2,500 Shares - MarketBeat
Vaxcyte (PCVX) officer surrenders shares to cover RSU taxes - Stock Titan
Vaxcyte (PCVX) CEO surrenders 3,685 shares to cover RSU taxes - Stock Titan
Vaxcyte (PCVX) CFO uses 1,021 shares to cover RSU tax withholding - Stock Titan
Vaxcyte (PCVX) finance SVP exercises options and sells 2,500 shares - Stock Titan
Vaxcyte (PCVX) COO logs planned stock sales and RSU tax withholding - Stock Titan
Jefferies reiterates Vaxcyte stock Buy rating on regulatory clarity By Investing.com - Investing.com South Africa
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):